Association of glutathione-S-transferase omega haplotypes with susceptibility to chronic obstructive pulmonary disease

Free Radical Research

Volumn 43, Issue 8, 2009, Pages 738-743

  Yanbaeva, Dilyara G ^a   Wouters, Emiel F M ^a,b   Dentener, Mieke A ^a   Spruit, Martijn A ^b   Reynaert, Niki L ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b Center for Integrated Rehabilitation of Organ Failure   (Netherlands)

Author keywords

COPD; FEV1; GST O; Polymorphism

Indexed keywords

ALANINE; ASPARAGINE; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE OMEGA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; FORCED EXPIRATORY VOLUME; GENE REPLICATION; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NUCLEIC ACID BASE SUBSTITUTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; VITAL CAPACITY;

AGED; CASE-CONTROL STUDIES; FEMALE; FORCED EXPIRATORY VOLUME; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTATHIONE TRANSFERASE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; NETHERLANDS; POINT MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; VITAL CAPACITY;

EID: 67650895656     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.1080/10715760903038440     Document Type: Article

References (19)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. Lancet 2001;367:1747-1757.
2. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-555.
3. Hallberg J, Dominicus A, Eriksson UK, Gerhardsson de Verdier M, Pedersen NL, Dahlback M, Nihlen U, Higenbottam T, Svartengren M. Interaction between smoking and genetic factors in the development of chronic bronchitis. Am J Respir Crit Care Med 2008;177:486-490.
4. Cheng SL, Yu CJ, Chen CJ, Yang PC. Genetic polymorphism of epoxide hydrolase and glutathione S-transferase in COPD. Eur Respir J 2004;23:818-824.
5. Harju TH, Peltoniemi MJ, Rytila PH, Soini Y, Salmenkivi KM, Board PG, Ruddock LW, Kinnula VL. Glutathione S-transferase omega in the lung and sputum supernatants of COPD patients. Respir Res 2007;8:48.
6. Whitbread AK, Tetlow N, Eyre HJ, Sutherland GR, Board PG. Characterization of the human Omega class glutathione transferase genes and associated polymorphisms. Pharmacogenetics 2003;13:131-144.
7. Peltoniemi MJ, Rytila PH, Harju TH, Soini YM, Salmenkivi KM, Ruddock LW, Kinnula VL. Modulation of glutaredoxin in the lung and sputum of cigarette smokers and chronic obstructive pulmonary disease. Respir Res 2006;7:133.
8. Wilk JB,Walter RE, Laramie JM, Gottlieb DJ, O'Connor GT. Framingham Heart Study genome-wide association: Results for pulmonary function measures. BMC Med Genet 2007;8(Suppl 1):S8.
9. Kotz D, Wesseling G, Huibers MJ, van Schayck OC. Efficacy of confrontational counselling for smoking cessation in smokers with previously undiagnosed mild to moderate airflow limitation: Study protocol of a randomized controlled trial. BMC Public Health 2007;7:332.
10. Gauderman WJ. Sample size requirements for matched casecontrol studies of gene-environment interaction. Stat Med 2002;21:35-50.
11. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002; 70:425-434.
12. Stram DO, Leigh Pearce C, Bretsky P, Freedman M, Hirschhorn JN, Altshuler D, Kolonel LN, Henderson BE, Thomas DC. Modeling and E-M estimation of haplotypespecific relative risks from genotype data for a case-control study of unrelated individuals. Hum Hered 2003;55:179-190.
13. Mukherjee B, Salavaggione OE, Pelleymounter LL, Moon I, Eckloff BW, Schaid DJ, Wieben ED, Weinshilboum RM. Glutathione S-transferase omega 1 and omega 2 pharmacogenomics. Drug Metab Dispos 2006;34:1237-1246.
14. Tanaka-Kagawa T, Jinno H, Hasegawa T, Makino Y, Seko Y, Hanioka N, Ando M. Functional characterization of two variant human GSTO 1-1s (Ala140Asp and Thr217Asn). Biochem Biophys Res Commun 2003;301:516-520.
15. Parvez F, Chen Y, Brandt-Rauf PW, Bernard A, Dumont X, Slavkovich V, Argos M, D'Armiento J, Foronjy R, Hasan MR, Eunus HE, Graziano JH, Ahsan H. Nonmalignant respiratory effects of chronic arsenic exposure from drinking water among never-smokers in Bangladesh. Environ Health Perpspect 2008;116:190-195.
16. Council NR. Arsenic in drinking water: 2001 update. Washington, DC: National Academy Press; 2001.
17. Dubey S, Powell CA. Update in lung cancer 2007. Am J Respir Crit Care Med 2007;177:941-946.
18. SeattleSNPs. Available online at: http://pga.gs.washington.edu/ (Accessed June 16 2008).
19. Laliberte RE, Perregaux DG, Hoth LR, Rosner PJ, Jordan CK, Peese KM, Eggler JF, Dombroski MA, Geoghegan KF, Gabel CA. Glutathione s-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1beta posttranslational processing. J Biol Chem 2003;278:16567-16578.